Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.

about

Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.

Item

http://www.wikidata.org/entity/Q38780843

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Outcome of autologous hematopo ...... n refractory multiple myeloma.

@en

type

Item

label

Outcome of autologous hematopo ...... n refractory multiple myeloma.

@en

prefLabel

Outcome of autologous hematopo ...... n refractory multiple myeloma.

@en

P1476

Outcome of autologous hematopo ...... in refractory multiple myeloma

@en

P2093

Chitra Hosing

http://www.w3.org/2001/XMLSchema#string

Denái R Milton

http://www.w3.org/2001/XMLSchema#string

Elisabet Manasanch

http://www.w3.org/2001/XMLSchema#string

Elizabeth J Shpall

http://www.w3.org/2001/XMLSchema#string

Hans C Lee

http://www.w3.org/2001/XMLSchema#string

Krina Patel

http://www.w3.org/2001/XMLSchema#string

Muzaffar H Qazilbash

http://www.w3.org/2001/XMLSchema#string

Partow Kebriaei

http://www.w3.org/2001/XMLSchema#string

Qaiser Bashir

http://www.w3.org/2001/XMLSchema#string

Richard E Champlin

http://www.w3.org/2001/XMLSchema#string

P2860

Recent advances in understanding multiple myeloma

Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma.

Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD.

Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma.

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.

Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease

P304

3568-3575

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.30770

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-05-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28513828

http://www.w3.org/2001/XMLSchema#string

P932

5656242

http://www.w3.org/2001/XMLSchema#string